Page last updated: 2024-12-07
oxyprothepine decanoate
Description
Oxyprothepine decanoate is an atypical antipsychotic medication that is a long-acting injectable form of oxyprothepine. It is used to treat schizophrenia and other psychotic disorders. Oxyprothepine decanoate is a dopamine and serotonin antagonist, which means that it blocks the effects of these neurotransmitters in the brain. This helps to reduce the symptoms of psychosis, such as hallucinations, delusions, and disorganized thinking. It is generally well-tolerated but can cause side effects such as weight gain, sedation, and movement disorders. The long-acting formulation allows for less frequent injections and improved medication adherence. The long-acting injectable formulation is particularly beneficial for patients who have difficulty adhering to oral medication regimens. The mechanism of action of oxyprothepine decanoate, its efficacy in treating various psychotic disorders, and its long-acting formulation are key areas of ongoing research. '
oxyprothepine decanoate: structure in Negwer, 5th ed, #5882 [Medical Subject Headings (MeSH), National Library of Medicine, extracted Dec-2023]
Cross-References
| ID Source | ID |
|---|
| PubMed CID | 93233 |
| SCHEMBL ID | 11841252 |
| MeSH ID | M0083902 |
Synonyms (17)
| Synonym |
|---|
| einecs 255-592-5 |
| 3-(4-(10,11-dihydro-8-(methylthio)dibenzo(b,f)thiepin-10-yl)piperazinyl)propyl decanoate |
| brn 0905225 |
| oxyprothepine decanoate |
| oxyprothepin decanoate |
| decanoic acid, 3-(4-(10,11-dihydro-8-(methylthio)dibenzo(b,f)thiepin-10-yl)-1-piperazinyl)propyl ester |
| decanoic acid, 3-(4-(10,11-dihydro-8-(methylthio)dibenzo(b,f)thiepin-10-yl)-1-piperizinyl)propyl ester |
| 3-[4-(3-methylsulfanyl-5,6-dihydrobenzo[b][1]benzothiepin-5-yl)piperazin-1-yl]propyl decanoate |
| 5-23-02-00470 (beilstein handbook reference) |
| kfh034qdi8 , |
| unii-kfh034qdi8 |
| 41931-86-6 |
| oxyprothepin decanoate [who-dd] |
| SCHEMBL11841252 |
| AKOS030593644 |
| Q27282228 |
| DTXSID70962065 |
Research
Studies (7)
| Timeframe | Studies, This Drug (%) | All Drugs % |
|---|
| pre-1990 | 6 (85.71) | 18.7374 |
| 1990's | 1 (14.29) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 0 (0.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| [information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023] |
Market Indicators
Research Demand Index: 11.89
According to the monthly volume, diversity, and competition of internet searches for this compound, as well the volume and growth of publications, there is estimated to be weak demand-to-supply ratio for research on this compound.
| Metric | This Compound (vs All) |
|---|
| Research Demand Index | 11.89 (24.57) | | Research Supply Index | 2.40 (2.92) | | Research Growth Index | 4.29 (4.65) | | Search Engine Demand Index | 0.00 (26.88) | | Search Engine Supply Index | 0.00 (0.95) |
| |
Study Types
| Publication Type | This drug (%) | All Drugs (%) |
|---|
| Trials | 3 (42.86%) | 5.53% |
| Reviews | 0 (0.00%) | 6.00% |
| Case Studies | 0 (0.00%) | 4.05% |
| Observational | 0 (0.00%) | 0.25% |
| Other | 4 (57.14%) | 84.16% |
| [information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023] |